Comparing metabolic and immune profiles in primary CNS diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective cohort study comparing metabolic and immunomic features between newly diagnosed primary CNS diffuse large B‑cell lymphoma patients, pathologically confirmed DLBCL patients without CNS involvement, and age- and sex-matched healthy donors. Baseline clinical information and biological samples will be collected, with PCNSL patients required to be treatment‑naïve at baseline. PCNSL participants will be followed every three months and asked to return sooner if symptoms develop. Laboratory analyses will profile metabolic signatures and immune characteristics to identify differences associated with CNS involvement.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged between 18 and 75 years.
2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
4. Case group patients must have complete supporting imaging and pathology data.

Exclusion Criteria:

1. Presence of other systemic malignancies.
2. Presence of severe infections or metabolic disorders.
3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
4. Pregnant or lactating women.
5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).
6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.

Where it's running

• The First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: 晓权 纪
• Email: jxqwd0901@163.com
• Phone: +8618159117171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Biobank Registry for Primary CNS Lymphoma in China

  This study will collect and register a long-term, multimodal biobank from adults with PCNSL to support future research, using patients with similar diagnoses as controls and healthy volunteers for comparison.

  Recruiting at 3 sites Beijing Tiantan Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07842835

• Zanubrutinib plus Lenalidomide for frail elderly with newly diagnosed PCNSL

  This study tests whether a combination of zanubrutinib and lenalidomide can help frail elderly patients with newly diagnosed primary CNS lymphoma.

  Recruiting Phase 2 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07839247

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.